Business · 19/08/2025

FDA Clears RIFADIN Capsules for Sale Despite Nitrosamine Impurities Concerns

The FDA has determined that RIFADIN (rifampin) capsules, 150mg and 300mg, were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving ANDAs that meet regulatory requirements.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Healthcare Business News Cybersecurity News Swap Clearing News Trade Regulation News CFTC Regulatory Updates Central Bank Policy News AI in Business News Small Business News Semiconductor News Supply Chain News Renewable Energy News Business Technology News Business Energy News Global Markets News Global Markets Business News Logistics and Supply Chain News Manufacturing and Industry News Investment and Capital News Climate and Business News Fintech for Business: Payments & Banking News

LATEST SIGNALS

Business · 10/9/2026

Center for Scientific Review Notice of Closed Meetings

The Center for Scientific Review has announced closed meetings for the following review groups: the Neurological Sciences A Study Section and the Neurological Sciences B Study Section.

Read summary →

Business · 10/5/2026

CDC Invites Public Comment on Proposed Data Collection for Public Health Crisis Response

The Centers for Disease Control and Prevention (CDC) is seeking public feedback on a proposed data collection project, titled Public Health Crisis Response (PHCR) Cooperative Agreement, which aims to rapidly fund public health programs responding to major emergencies and crises, as required by the Paperwork Reduction Act of 1995.

Read summary →

Business · 10/5/2026

CDC Requests Public Comment on Respiratory Protective Devices Data Collection

The Centers for Disease Control and Prevention (CDC) is seeking public input on a proposed data collection project related to Respiratory Protective Devices, as required by the Paperwork Reduction Act of 1995, to inform the approval certification activities under 42 CFR part 84.

Read summary →

Business · 10/5/2026

Federal Agencies Review Forms Under the Paperwork Reduction Act

The Paperwork Reduction Act is being reviewed by federal agencies to streamline and simplify the paperwork process, aiming to reduce bureaucratic burdens on the public.

Read summary →

Business · 10/5/2026

Center for Scientific Review Amends Meeting Notice

The Center for Scientific Review has updated its meeting notice, making the details publicly available.

Read summary →

Business · 9/28/2026

CDC Invites Public Comment on Proposed Data Collection for Public Health Emergency Preparedness

The Centers for Disease Control and Prevention (CDC) is seeking public input on a proposed data collection project, titled Public Health Emergency Preparedness (PHEP) Cooperative Agreement, as part of its efforts to reduce public burden and maximize the utility of government information, in accordance with the Paperwork Reduction Act of 1995.

Read summary →